CG Oncology (CGON) is trading lower as the market refocuses on potential dilution risk tied to the company’s expanded at-the-market (ATM) stock sale program. In an SEC prospectus amendment dated January 13, 2026, CG Oncology increased the maximum aggregate offering size of its ATM program to up to $550 million, after selling $250 million under the prior limit—highlighting the company’s ability to issue additional shares over time via Jefferies as sales agent.

ATM capacity doesn’t guarantee immediate issuance, but it creates an overhang: investors often discount biotech equities when large, flexible sell-from-time-to-time programs are in place, especially after sizable price appreciation. With CGON up sharply over the past six months, today’s drop fits a common pattern of profit-taking and de-risking as traders reassess how future capital raises could affect per-share value.

The selling pressure is arriving as CG Oncology’s core thesis remains centered on cretostimogene and multiple bladder-cancer studies, including the Phase 3 PIVOT-006 program, where topline data has been guided for the first half of 2026. Separately, earlier corporate updates emphasized ongoing regulatory work, including a rolling BLA submission strategy with a complete submission expected in 2026, which keeps the stock sensitive to any perceived financing needs or timeline risk.